Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to establish the maximum tolerated dose and
recommended Phase II dose of Erbitux™ in combination with Irinotecan in pediatric and
adolescent patients with refractory solid tumors.